--- a
+++ b/clusters/3009knumclusters/clust_42.txt
@@ -0,0 +1,405 @@
+CD4 count >= 50 cells/ul
+Granulocytes >= 1,500/ul
+Neutrophils >= 1000/uL
+Granulocytes >= 1,500/ul
+Platelet count >= 100,000/ul
+Platelet count >= 100,000/uL, obtained within 4 weeks prior to randomization
+Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
+Platelet count >= 75,000/uL
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 90 days prior to step 1 registration
+Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement
+Platelet count >= 50,000/uL for patients with solid tumors and known bone marrow metastatic disease
+Platelet count >= 50,000/uL (unless documented bone marrow involvement with lymphoma)
+Platelet count (PLT) >= 100,000/uL (>= 30 X 10^9/L), within 14 days of registration
+Platelet count >=100,000/ul
+Platelet count >= 50,000/ul; for patients with >= 50% plasma cell involvement of the bone marrow, platelet count >= 30,000/ul is acceptable
+Platelet count >= 100,000/ul (>= 100,000 per mm^3) must be met within 28 days of C1D1
+Platelet count >= 75,000/ul (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
+Platelet count of >= 100,000/uL
+Platelet count > 100,000/uL
+Platelet count >= 100,000/uL, within 14 days of registration
+Platelet count >= 50,000/uL
+Platelet count ? 100,000/uL
+Platelet count >= 75,000/uL (transfusion independent for >= 7 days)
+Platelet count (PLT) < 100,000/ul or
+Platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to enrollment) for subjects without bone marrow involvement
+Platelet count < 100,000/uL without full-dose anticogulation therapy
+Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count ? 75,000/uL (transfusion independent)
+Absolute lymphocyte count >= 150/uL
+While blood cells 2000/ul or more
+Obtained within 14 days prior to registration: Platelet count >= 150,000/uL
+Platelet count >= 100 K/uL within 14 days prior to start of protocol therapy.
+Platelet count ? 75,000/uL\r\n* The above criteria do not have to be met if the patient has bone marrow involvement of tumor
+Lymphocyte count > 500/uL
+Platelet count > 100,000/uL
+PHASE I: Platelet count >= 100,000/uL
+PHASE IB: Platelet count >= 100,000/uL
+OBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Platelet (PLT) >= 100,000/uL
+Platelets >= 75,000 cells /uL (unsupported, defined as no platelet transfusion within 7 days)
+Platelet count of >= 100,000/uL
+Platelet count < 75,000/uL
+Platelet count > 100,000/ul within four weeks of enrollment
+Absolute lymphocyte count (ALC) >= 100 cells/ul
+Platelet count >= 75,000/uL (transfusion independent)
+Platelet count >= 75,000 K/uL
+Platelet count >= 100,000/uL
+Absolute lymphocyte count (ALC) of > 5,000 K/uL
+Lymphocyte count >= 300/uL.
+Platelet count >= 100,000/uL.
+TREATMENT WITH SJCAR19: Platelet count > 20,000/uL (can be transfused)
+Platelet count < 100,000/uL
+Platelet count >= 50,000/uL without transfusional support in the previous 7 days
+CD4 gene count > 200/ul
+Platelet count ? 50,000/uL, with or without transfusion support
+Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000 uL
+Neutrophils >= 1500/uL.
+Platelets >= 50,000/mm^3 for MCL cohort and platelets >= 75,000/mm^3 for DLBCL cohort, performed within 14 days prior to day 1 of protocol therapy\r\n* NOTE: platelet transfusions and packed red blood cell transfusion can be given prior to enrollment to achieve a target platelet (Plt) >= 50,000/uL for MCL and >= 75,000/uL for DLBCL and hemoglobin of >= 8.5 g/dL
+Within 28 days prior to treatment start: Platelet count >= 100,000/ul
+Absolute lymphocyte count > 100/uL.
+Platelet count >= 30,000/uL
+Platelet >= 75,000/uL
+STUDY TREATMENT: Lymphocyte count >= 300/uL within 14 days prior to the first study treatment.
+STUDY TREATMENT: Platelet count >= 100,000/uL within 14 days prior to the first study treatment.
+Absolute lymphocyte count >= 1000/ul
+Platelet count >= 100,000/uL (no platelet transfusion within 7 days prior to obtaining laboratory result)
+Platelet count >= 100,000/uL
+While blood cells 2000/ul or more
+Platelet count >= 100 x 10^9/L (>= 100,000 /uL)
+Platelet count =< 100,000 x 10^9/uL at the screening visit
+Platelet count > 100,000/uL without platelet transfusion within the past 7 days
+While blood cells 2000/ul or more
+Lymphocyte count >= 300/uL.
+Platelets >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or core is > 30%, platelet eligibility requirement will be adjusted to 60,000/ul
+Platelet count >= 100,000 cells/uL
+Obtained within 14 days of the first study treatment: Lymphocyte count > 500/uL
+Obtained within 14 days of the first study treatment: Platelet count > 100,000/uL
+Platelet count > 20 K/uL
+Platelet count >= 100,000/uL
+CD4 count > 200/uL
+Platelet (PLT) count > 80 K/uL
+Platelet count > 75,000/uL unless disease-related (due to marrow infiltration or splenomegaly)
+Platelet >= 100 x 10^3/uL within 14 days of registration
+Platelet count of >= 100,000/uL
+Obtained within 14 days of the first study treatment: Lymphocyte count >500/uL
+Obtained within 14 days of the first study treatment: Platelet count > 100,000/uL
+Platelet count >= 50,000/uL
+Lymphocyte count >= 300/uL
+Platelet count < 100,000/uL
+Lymphocyte count >= 300/uL
+Platelet count >= 100,000/uL
+Platelet count < 35 K/uL
+Platelet count >= 100,000/ul within 14 days of cycle 1 day 1
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): lymphocyte count >= 500/uL
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): platelet count >= 100,000/uL
+STUDY TREATMENT: Neutrophils >= 1500/ul
+Platelet count > 75,000/uL
+Within 14 days prior to cycle 1 day 1 of treatment: Absolute lymphocyte count >= 500/uL
+Within 14 days prior to cycle 1 day 1 of treatment: Platelet count >= 100,000/uL
+Platelet count of greater than 20,000/ul, with no platelet transfusion in prior 2 weeks
+Neutrophils >= 1500/uL
+Neutrophils >= 1500/uL
+Platelet count >= 100,000/uL
+Platelet count (PLT) >= 100,000/uL obtained =< 14 days prior to registration
+Neutrophils >= 1500/uL
+Platelet count greater than or equal to 100,000/uL
+Platelet count >= 125,000/uL prior to biopsy; platelets >= 100,000/uL prior to infusion
+Platelet count >= 100,000/uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uL
+Lymphocyte count >= 300/uL
+Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uL
+Platelet count >= 75,000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
+Platelet ? 75,000/uL
+Absolute lymphocyte count ? 100/uL
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count ?75,000/uL
+Platelet count (plt) >= 100,000/ uL (obtained within 28 days prior to first study treatment)
+Absolute lymphocyte count >= 500 cells/uL (obtained within 28 days prior to first study treatment)
+Within 14 days of registration: Platelet count >= 100,000/ul
+Platelet (Plt) >= 75,000/uL
+Lymphocyte count ? 300/uL within 14 days prior to the first study treatment (cycle 1, day 1)
+Platelet count ? 100,000/uL within 14 days prior to the first study treatment (cycle 1, day 1)
+Platelet count >= 125,000/ul prior to biopsy; platelet count >= 100,000/ul prior to infusion
+Neutrophils >= 1500/uL
+Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
+Platelet count (PLT) >= 75,000/uL obtained =< 14 days prior to registration
+Neutrophils >= 1500 /uL
+Absolute lymphocyte count >= 400/uL
+Platelet count >= 100,000/uL
+Platelet count >= 100,000 cells/uL
+Platelet count >= 50,000/uL
+Neutrophils >= 1500/uL
+Platelet count of >= 95,000/uL
+Platelet count of >= 85,000/ul
+Platelet count of >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
+Platelet count >= 100,000/uL (transfusion independent)
+Platelets >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days\r\nprior to laboratory sample)
+Platelet count >= 75,000/ul (unless documented bone marrow involvement with lymphoma)
+Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
+Platelet count >= 100,000/uL independent of transfusion and or growth factors within 3 months prior to enrollment
+Platelet count >= 100,000/uL within 30 days prior to C1D1
+CD4 count >= 100 cells/uL if HIV-infected
+Platelet count >= 100,000/uL
+Platelet count > 75K/uL
+Platelet count >= 100,000 platelets/ul
+Absolute lymphocyte count < 500/uL
+Contraindications to TAS-102\r\n* Absolute neutrophil count < 1,500/ul\r\n* Platelet count < 75,000/ul\r\n* Allergy or intolerance to TAS-102
+Lymphocyte count >= 300/uL
+Platelet count >= 100,000/uL
+Neutrophils >= 1500/uL
+Within 3 months of registration: Platelet count (plt) >= 100,000/uL
+Platelet count < 75,000/uL
+Absolute lymphocyte count >= 500/ul
+Platelet count >= 50,000/ul (transfusion independent)
+Platelet count >= 100,000/uL
+ARM A COHORT 1: Platelet count >= 100,000/ul
+ARM B COHORT 2: Platelet count >= 100,000/ul
+ARM B COHORT 3: Platelet count >= 100,000/ul
+ARM C COHORT 4: Platelet count >= 100,000/ul
+Neutrophils >= 1500/uL
+Absolute lymphocyte count (ALC) >= 500/uL
+Lymphocyte count >= 500/uL
+Platelet count >= 100,000/uL
+Bone marrow examination revealing myelodysplastic syndrome or megakaryocyte underproduction for patients with a platelet count < 50,000/uL
+Absolute lymphocyte count of >= 500/uL
+Must be met within 28 days of C1D1: Platelet count >= 100,000/ul
+Absolute lymphocyte count (ALC) >= 100 cells/ul
+Platelet (PLT) >= 75,000/uL, obtained =< 14 days prior to registration
+Platelet >= 75,000/uL
+Platelet count 50,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment. Exception: Patients that are platelet dependent due to previous extensive treatment- e.g. - MIBG therapy).
+Platelet count >= 80,000/uL
+Platelet (PLT) >= 100,000/uL (obtained =< 7 days prior to registration)
+Platelet count >= 100,000/uL
+Platelet count >= 100,000/uL
+Leukocyte >= 3,000/ul
+Platelet count >= 100,000 cells/uL
+Absolute lymphocyte count of >= 500/uL
+Absolute lymphocyte count >= 500/ul (phase I only)
+Platelet count >= 25,000/ul (phase I only)
+Platelet count >= 100,000/uL
+Platelet count >= 50 x 10^9 /uL without platelet transfusions
+Platelet count >= 100,000/ul
+Platelet count >= 100,000/uL (transfusion independent)
+Absolute lymphocyte count >= 500/ul
+Platelet count >= 25,000/ul
+Platelet count >= 80 K/uL (in the expansion cohorts, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uL), without platelet transfusions for 1 week
+Absolute lymphocyte count of > 500/uL
+Platelet count >= 100,000/uL (may be a post transfusion value)
+Full hematologic recovery following Auto HCT including:\r\n* Absolute neutrophil count (ANC) >1000 ul\r\n* Platelet count of >= 50,000 ul independent of transfusion for >7 days
+Platelet count < 25,000/ul
+Platelet > 75,000/uL
+Obtained =< 14 days prior to registration: Un-transfused platelet count >= 75000/uL (>= 50,000/uL if marrow plasma cells [PC]% > 50%)
+Absolute lymphocyte count (ALC) > 800/ul
+Platelet count > 100,000/uL during screening evaluation
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count >= 100,000 cells/ul
+Platelet count: >= 50,000/ul, transfusion independent (no platelet transfusions within 1 week)
+Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL.
+Within 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000uL for patients with hematologic malignancies, platelet count >= 75,000/uL.
+Platelet count >/= 100,000 platelets/ul prior to initial treatment
+Platelet count >= 100,000/uL
+Platelet count >= 50,000/ul
+Obtained =< 7 days prior to registration: Platelet count >= 100,000/uL
+Lymphocyte count >= 300/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
+Platelet count >= 100,000/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
+Platelet count >= 75,000/uL
+Patients with very low CD4 counts (< 200/uL or 14% of total lymphocyte count)
+Platelet count >= 50,000/uL; platelet transfusion is not permitted within 7 days of screening
+Platelet count >= 50,000/uL
+Platelet count >= 100,000/uL
+Absolute lymphocyte count (ALC) >= 800/uL
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count >= 100,000/uL
+Cluster of differentiation 4 (CD4) count >= 200/uL
+Neutrophils >= 1500/uL
+Obtained within 14 days (or as stipulated) prior to study drug (treatment) administration: platelet count ? 50,000/ul (without platelet transfusion in the previous 5 days)
+Platelet count >= 150,000/ul
+Platelet count >= 100,000/ul (no platelet transfusion for more than 3 days)
+Secondary Registration: absolute lymphocyte count >= 200/uL
+Absolute neutrophils > 1,500/uL
+Platelet >= 100,000/uL
+Platelet count >= 100,000/uL
+Platelet count > 100,000/uL (transfusion independent)
+Platelet count >= 75,000/uL (transfusion independent)\r\n* If the ANC and/or platelet count are not adequate, but due to bone marrow metastatic disease, these criteria will be waived
+Lymphocyte count >= 500/uL
+Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uL
+For patients with solid tumors without bone marrow involvement: platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
+For patients with solid tumors and known bone marrow metastatic disease: platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/uL (transfusion independent)
+Platelet count >= 75,000 cells/uL
+Platelet count > 100,000/ul
+Platelet count < 50,000/uL, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)
+Patients must have a platelet count >= 20,000/uL at the time of the initial evaluation
+Platelet (PLT) = 100,000/uL
+Granulocyte count of at least 1,500/uL
+Platelet count of greater than 100,000/uL
+Platelet count >= 100,000/uL
+Granulocytes >= 1,000/uL
+Platelet count >= 75,000/uL
+Platelet count >= 100,000/uL (transfusion independent)
+Neutrophils >= 1,500 cells/uL
+Neutrophils >= 1500 cells/uL
+Platelet count >= 100,000/ul
+Platelet count > 100,000/ul
+Absolute lymphocyte count of > 20,000 cells/ul or symptomatic splenomegaly
+Platelet count >= 100,000/UL
+Platelet count >= 100,000/uL
+Platelet >= 75,000/uL
+Granulocyte count >= 1,000/uL for lapatinib and > 1,500/uL for capecitabine
+Platelet count >= 100,000/uL
+Platelets >= 100,000/ul (no platelet transfusion allowed within 2 weeks)
+CD4+ T-cell count >= 100 cells/uL
+Granulocytes >= 1,500/uL
+Platelet count >= 100,000/uL
+Platelet count >= 100,000ul
+Platelet ? 100,000 / uL
+Granulocytes >= 1,500/uL
+Platelet count >= 100,000/uL
+Neutrophils >= 1500 cells/uL
+Platelet count > 75,000/uL
+Neutrophils >= 1500/uL
+Platelet count (untransfused) >= 30,000/uL
+Absolute lymphocyte count >= 500/uL
+Platelet count >= 75,000/uL (transfusion independent)
+Platelet count > 75,000/uL
+Platelet count > 25 K/uL
+One of the following diagnoses:\r\n* MDS with International Prognostic Scoring System (IPSS) score of INT-1 or higher and one of the following:\r\n** Symptomatic anemia with either hemoglobin < 10.0 g/dL or requiring red blood cell (RBC) transfusion\r\n** Thrombocytopenia with a history of two or more platelet counts < 50,000/uL or a significant hemorrhage requiring platelet transfusions\r\n** Neutropenia with two or more absolute neutrophil count (ANC) < 1,000/uL\r\n* Non-M3 AML
+Peripheral blood blast count < 10,000/uL
+Presence of significant active bleeding or condition requiring maintenance of a platelet count > 50,000/uL
+Neutrophils > 1500/uL
+Platelet count > 30,000 K/uL independent of transfusion support
+Platelet count >= 100,000/uL
+Platelet count > 100,000/uL or > 75,000/uL if bone marrow (BM) involvement or splenomegaly
+Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 500/uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uL
+Absolute lymphocyte count (ALC) >= 250/uL obtained =< 7 days prior to registration
+Platelet count (PLT) >= 75,000 /uL without transfusions obtained =< 7 days prior to registration
+Neutrophils >= 1500/uL
+Platelet count > 100,000/ul
+Platelet count >= 100,000/uL
+Platelet count >= 80 K/u (in the Phase IIa portion, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uL)
+Platelet count >= 100,000/uL
+Platelet count >= 100,000 cells/uL
+Platelet count >= 75,000/uL for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count >= 50,000/uL for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; platelet transfusions are not allowed within 3 days of last platelet assessment to confirm eligibility
+Platelet count >= 100,000/uL
+Platelets >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or core is > 30%, platelet eligibility requirement will be adjusted to 60,000/uL
+Platelet count >= 100,000/ul
+Platelet count < 50,000/uL
+Platelet count > 100,000/uL without platelet transfusion within the past 7 days
+The platelet count must be at least 100,000/uL
+Platelet count >= 100 x 10^3/uL
+Platelet count greater than or equal to 100,000/uL
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); lymphocyte count ? 300/uL
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); platelet count ? 75,000/uL
+Platelet count >= 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissible
+Untransfused platelet count >= 75,000/uL
+Granulocytes >= 1,500/uL
+Platelet count >= 100,000/uL
+Thrombocytopenia (platelet count < 100 x 10^3/uL)
+Platelet count >= 50,000/uL
+Platelet count >= 20,000/ul without transfusion for 7 days
+Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count of less than 35,000/uL
+Platelet count >= 100,000/uL obtained within 2 weeks prior to enrollment
+Platelet count =< 100,000/uL
+Platelet count >= 70 K/uL, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uL
+Absolute lymphocyte count >= 500/ul
+Platelet count >= 25,000/ul
+Obtained within 14 days prior to registration: Platelet count >= 100,000/ul
+Neutrophils > 1,000/uL prior to day 0
+Platelet count >= 100,000/uL (transfusion independent)
+Neutrophils > 1000/uL
+Neutrophils > 1500/uL
+Granulocytes >= 1000/ul
+Platelet count >= 75,000/ul
+Neutrophils > 1000/uL
+Platelet count >= 125,000/ul prior to biopsy; platelets >= 100,000/ul prior to infusion
+Platelet count >= 100,000/uL
+Platelet (PLT) >= 75,000/uL
+Platelet (PLT) count >= 20K/uL, unless attributed to marrow infiltration with CLL
+Platelet count >= 100,000/uL
+Platelet count >= 100,000/uL within 30 days prior to registration
+Neutrophils >= 1500/uL
+Lymphocyte count >= 300/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])
+Platelet count >= 75 K/uL, unless if cytopenias are deemed to be due to disease at discretion of clinical investigator; transfusions and growth factors are permissible
+Granulocytes >= 1,500/ul
+Platelet count >= 100,000/ul
+Minimum absolute neutrophil count of 1,000 cells/ul and minimum platelet count (without transfusion) of 20,000/mm^3; values below these levels may be accepted at the discretion of the PI, if thought to be due to bone marrow involvement by malignancy
+Platelet count > 50,000/ul
+Platelet count >= 150,000/uL
+Platelet count of > 100,000/ul
+Neutrophils > 1500/uL
+Platelet count >= 50,000/ul
+Thrombocytopenia (platelet count < 100 x 10^3/uL)
+Circulating blast count >= 50,000/uL within the week preceding enrollment
+Platelet count must be >= 100,000/uL
+Absolute CD4+ lymphocyte count: >= 75 cells/uL
+Neutrophils >= 1,000/ul
+Platelet count >= 100,000/uL
+Granulocytes >= 1500/ul
+Platelet count >= 75,000/ul
+Absolute lymphocyte count > 500/uL
+Platelet (PLT) >= 100,000/uL
+ALC >100/uL
+Platelet count ? 75,000/uL
+Platelet count (Plt) >= 75,000/uL
+Platelet count > 75,000/ ul 3
+Platelet count >= 100,000/uL
+Platelet count >= 75,000/uL (transfusion independent)
+Platelet count >= 75,000/uL for patients with solid tumors without bone marrow involvement (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); platelet count >= 25,000/uL for patients with known bone metastatic disease (transfusions are permitted to reach the platelet criteria)
+Platelet >= 75,000/uL
+Platelet count >= 100,000/uL (without transfusion within 2 weeks prior to cycle 1, day 1)
+Platelets >= 100,000/ul; low platelet counts may be corrected with transfusion to achieve eligibility for study
+Platelet count >= 100,000/ul
+CROSSOVER (STEP 2) REGISTRATION: Platelet count >= 100,000/ul
+Platelet count >= 75,000/uL (transfusion independent)
+Platelet count >= 75 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)
+Platelet count >= 100,000/ul
+Platelet >= 100,000/uL
+Platelet count >= 75,000/uL
+(Untransfused) platelet count >= 50000/uL
+Thrombocytopenia (<30,000/uL)
+Untransfused platelet count >= 75000/uL
+Platelet count > 100‚000/uL
+Platelet count: 100,000/ul and transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)
+Platelet count >= 100,000/uL
+Granulocyte count >= 1,000/uL
+Platelet count >= 100,000/uL
+Platelet count of >= 100,000/uL
+Neutrophils > 1000/uL
+Platelet count greater than or equal to 25,000/uL
+Platelet count > 100,000/uL (transfusion independent)
+Neutrophils >= 1500/uL
+Platelet count < 100,000/uL
+Platelets >= 75,000/uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to complete blood count (CBC) documenting eligibility
+Lymphocyte count >= 500/uL (obtained within 28 days prior to the first study treatment)
+Platelet count >= 100,000/uL (obtained within 28 days prior to the first study treatment)
+Platelet count >= 50,000/ul (corrected if needed)
+Platelet count >= 100,000/uL
+Platelet count >= 100,000/uL
+Platelet count >= 50,000/uL
+Platelet count > 100,000/uL
+Platelet count > 100,000/ul
+Platelet count ? 75x109/L (75,000/uL) without transfusion
+Platelet count >= 75,000/uL (> 72 hours since prior platelet transfusion)
+Platelet count: 10-600/uL
+Stable platelet count >= 75,000/mm^3 (>= 75 k/uL)
+Platelet count >= 100,000/ul
+Platelet count >= 100,000/uL, obtained within 14 days prior to treatment start
+Obtained within 28 days prior to registration: Platelet count (plt) >= 100,000/uL
+Obtained within 28 days prior to registration: Absolute lymphocyte count >= 500 cells/uL
+Platelet count of =< 50,000/uL
+Existing major organ dysfunction > grade 2, with the exception of myelosuppression (neutrophil count >= 500/ul and platelet count >= 25,000/ul are acceptable) and hearing loss
+Platelet count has to be >= 100,000/uL in patients undergoing biopsy
+Platelet count (PLT) > 100 K/uL
+Platelet count >= 100,000/uL
+Unacceptable hemogram: white blood cell count < 3,800/ul or > 10,500/ul
+Unacceptable hemogram: platelet count < 75,000/ul
+Platelet count >= 100,000/uL (transfusion independent)
+Lymphocyte count >= 500/uL
+Platelet > 50,000/uL
+Platelet count > 100‚000/uL